CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore patent oppositions filed by Genmab against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Aug 7, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Use Of Trl Agonist And Anti-Cd47 Agent To Enhance Phagocytosis Of Cancer CellsTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJun 29, 2022
Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLINDHOFERNov 17, 2021
Methods For Manipulating Phagocytosis Mediated By Cd47THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJan 17, 2020
Methods For Manipulating Phagocytosis Mediated By Cd47THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJan 17, 2020
Methods For Achieving Therapeutically Effective Doses Of Anti-Cd47 AgentsTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJan 3, 2020
Cytotoxicity-Inducing Therapeutic AgentCHUGAI SEIYAKU KABUSHIKI KAISHAJun 12, 2019

Explore Genmab's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 7, 2025
Patent NumberGrant DateTitleTotal Oppositions
Jan 3, 2024Bispecific And Multispecific Antibodies And Method For Isolation Of Such2
Feb 26, 2020Inert Format2
Jul 17, 2019Antibodies Against Cd38 For Treatment Of Multiple Myeloma1
Jan 2, 2019Antibodies Against Cd38 For Treatment Of Multiple Myeloma1
Apr 25, 2018High Througput Methods For Characterization Of Antibodies1

Top competitors of Genmab

List of top competitors of Genmab based on patent oppositions.